IMPLICATION OF HUMAN FC RECEPTORS POLYMORPHISM IN CHILDHOOD IMMUNE THROMBOCYTOPENIC PURPURA

被引:0
作者
Starcea, Iuliana Magdalena [1 ]
Rosu, V. E. [1 ]
Ivanov, Anca Viorica [1 ]
Mirou, Ingrith Crenguta [1 ]
Popescu, Roxana [1 ]
Antoci, L. M. [1 ]
Ciobanu, C. G. [1 ]
Spoiala, Elena-Lia [1 ]
Lupu, V. V. [1 ]
Rosu, Solange Tamara [2 ]
Alecsa, Mirabela-Smaranda [1 ]
Rusu, Carmen Daniela [3 ]
Lupu, Ancuta [1 ]
Gavrilovici, Cristina [1 ]
机构
[1] Grigore T Popa Univ Med & Pharm Iasi, Fac Med, Dept Mother & Child Med, Iasi, Romania
[2] Grigore T Popa Univ Med & Pharm Iasi, Fac Med, Dept Med Specialties II, Iasi, Romania
[3] Grigore T Popa Univ Med & Pharm Iasi, Fac Med, Dept Surg II, Iasi, Romania
来源
MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA | 2023年 / 127卷 / 02期
关键词
FCGR POLYMORPHISM; IMMUNE THROMBOCYTOPENIC PURPURA; CHILDREN; PLATELETS; COPY NUMBER VARIATION; GAMMA-RIIA; LINKAGE DISEQUILIBRIUM; IMMUNOGLOBULIN-G; IGG; DISEASE; IIA; PHAGOCYTOSIS; PATHOGENESIS; ASSOCIATION;
D O I
10.22551/MSJ.2023.02.14
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Immune thrombocytopenic purpura (ITP) is the most frequent form of autoimmune disease in childhood, characterized by thrombocytopenia (platelet count <150 & BULL;10(9)/L) with otherwise normal cell lineages. One of the main mechanisms is the platelet destruction by phagocytic cells, covered by human Fc receptors (FCGR). The FCR family involves 3 classes of receptors: FCGR1A, 1B, and 1C; FCGR2A, 2B, and 2C; FCGR3A and 3B, all present on chromosome 1q23-24. The response to ITP treatment may be influenced by the polymorphism of the FCGR3A gene, which contributes to different levels of destruction of antibody -bound platelets. Material and methods: We report the results of FCGR2/3 polymorphic genotypes in 16 children with ITP admitted at the "Sf. Maria" Emergency Children's Hospital, Iasi, Romania, treated with corticosteroids, intravenous immunoglobulin (IVIg) or both, or conservative treatment, with a minimum of one year follow up. Results: We identified 9/16 patients with FCGR2C ORF haplotypes, 8 in heterozygous state and one in homozygous state, and 15/16 patients with FCGR2A-His166 variant. While it was previously reported that classical FCGR2C-ORF and 2B.4 variants correlate with the transient form of ITP and a good response to IVIg, in our sample it was present only in 3 patients, who had limited course of disease and a good response to IVIg. 5 patients were heterozygotes for FCGR2C-p.Gln62Trp, all of them developing an acute form, a good response to IVIg and no relapses. Furthermore, it has been demonstrated an association between FCGR genotypes characterized by increased immunoglobulin binding activity (FCGR3A allele V158 and FGCGR3B allele NA1) and chronic children ITP. In our study, only 2/16 patients express NA1 in homozygous state, one of them developing persistent ITP, while the other responded well to the treatment and did not relapse. Conclusions: Genetic influences contribute to the pathogenesis of ITP in children and response to IVIg. We evaluated the genetic risk factors in the FCGR2/3 locus that are associat-ed with predisposition to limited course and a favorable response to IVIg in ITP in children. However, confirmation in a larger prospectively recruited cohort of children with ITP is needed.
引用
收藏
页码:260 / 274
页数:15
相关论文
共 50 条
  • [41] Helicobacter pylori induced Immune Thrombocytopenic Purpura and perspective role of Helicobacter pylori eradication therapy for treating Immune Thrombocytopenic Purpura
    Ihtesham, Arham
    Maqbool, Shahzaib
    Nadeem, Muhammad
    Janjua, Muhammad Bilawal Abbas
    Sundus, Omaima
    Naqqash, Ali Bakht
    Mohamed, Waleed Inayat
    Haider, Syed Turab
    Ahmad, Muhmmad
    Mustafa, Mir Ahmad Talha
    Mehboob, Hafiz Osama
    AIMS MICROBIOLOGY, 2021, 7 (03): : 284 - 303
  • [42] THE ASSOCIATION OF IMMUNE THROMBOCYTOPENIC PURPURA WITH HEREDITARY SPHEROCYTOSIS
    Sac, Rukiye
    Guveloglu, Mine
    Bostanci, Ilknur
    Tazegul, Aysu
    Dallar, Yildiz
    MARMARA MEDICAL JOURNAL, 2009, 22 (02): : 142 - 145
  • [43] Combined immune thrombocytopenic purpura and immunoglobulin A nephropathy: a similar pathophysiologic process?
    Kahraman, Cuneyt
    Emre, Habib
    Gulcan, Erim
    Bilen, Yusuf
    Uludag, Koray
    Uyanik, Abdullah
    Keles, Mustafa
    RENAL FAILURE, 2014, 36 (03) : 464 - 465
  • [44] Immune thrombocytopenic purpura in childhood in Norway: A prospective, population-based registration
    Zeller, B
    Helgestad, J
    Hellebostad, M
    Kolmannskog, S
    Nystad, T
    Stensvold, K
    Wesenberg, F
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2000, 17 (07) : 551 - 558
  • [45] Anti-β2-glycoprotein I in childhood immune thrombocytopenic purpura
    El-Bostany, Eman A.
    El-Ghoroury, Eman A.
    El-Ghafar, Esmat A.
    BLOOD COAGULATION & FIBRINOLYSIS, 2008, 19 (01) : 26 - 31
  • [46] Comparison of intravenous immune globulin and high dose anti-D immune globulin as initial therapy for childhood immune thrombocytopenic purpura
    Kane, Ian
    Ragucci, Dominic
    Shatat, Ibrahim F.
    Bussel, James
    Kalpatthi, Ram
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (01) : 79 - 83
  • [47] Association of interleukin-(IL)10 haplotypes and serum IL-10 levels in the progression of childhood immune thrombocytopenic purpura
    Tesse, Riccardina
    Del Vecchio, Giovanni Carlo
    De Mattia, Domenico
    Sangerardi, Maria
    Valente, Federica
    Giordano, Paola
    GENE, 2012, 505 (01) : 53 - 56
  • [48] Recombinant human interferon α-2a therapy in children with chronic immune thrombocytopenic purpura
    Hrstková, H
    Bajer, M
    Michálek, J
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2002, 24 (04) : 299 - 303
  • [49] Evaluation of clinical characteristics, diagnosis and management in childhood immune thrombocytopenic purpura:: a single center's experience
    Kocak, Uelker
    Aral, Yusuf Ziya
    Kaya, Zuehre
    Oeztuerk, Guelyuez
    Guersel, Tuerkiz
    TURKISH JOURNAL OF PEDIATRICS, 2007, 49 (03) : 250 - 255
  • [50] Vaccine administration and the development of immune thrombocytopenic purpura in children
    Cecinati, Valerio
    Principi, Nicola
    Brescia, Letizia
    Giordano, Paola
    Esposito, Susanna
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (05) : 1158 - 1162